1. Cytoskeleton
  2. Integrin
  3. Vedolizumab (anti-α4β7-integrin)

Vedolizumab (anti-α4β7-integrin) 

目录号: HY-P9911A 纯度: 99.90%
COA

Vedolizumab (anti-α4β7-integrin) 是一种靶向 α4β7 整联蛋白 (integrin) 的人源化 IgG1 单克隆抗体,用于溃疡性结肠炎和克罗恩病的相关研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

CAS No. : 943609-66-3

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥1700
In-stock
5 mg ¥4500
In-stock
10 mg ¥6975
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease[1][2].

同型

Human IgG1 kappa

推荐同型对照抗体
种属

Humanized

体外研究
(In Vitro)

Vedolizumab does not bind to the majority of memory CD4+ T lymphocytes (60%), neutrophils, and most monocytes. The highest level of vedolizumab binding is to a subset (25%) of human peripheral blood memory CD4+ T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; vedolizumab binds to memory CD4+ T and B lymphocytes with subnanomolar potency (EC50=0.3-0.4 nM). Vedolizumab selectively inhibits adhesion of α4β7-expressing cells to mucosal addressin cell adhesion molecule 1 (IC50=0.02-0.06 μg/mL) and fibronectin (IC50=0.02 μg/mL), but not vascular cell adhesion molecule 1[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CAS 号
性状

固体

颜色

White to off-white

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

Format
  • Human IgG1 kappa
纯度 & 产品资料

纯度: 99.90%

参考文献

Vedolizumab (anti-α4β7-integrin) 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Vedolizumab (anti-α4β7-integrin)
目录号:
HY-P9911A
需求量: